Schaeffer Scholars Alison Sexton Ward and Dana Goldman argue in a Washington Post op-ed that Medicare’s decision not to broadly cover highly effective anti-obesity medications is a missed opportunity, citing research Schaeffer Center research finding that expanded access to the drugs would generate substantial societal benefits.
“If [Centers for Medicare and Medicaid Services] administrators reconsider the policy — and we believe they should — Medicare and Medicaid should require manufacturers to deliver savings as a condition of coverage,” they suggest. “Given the earnings potential, the drugmakers would probably be eager to accept.”
Read their op-ed here.
